News

Introduction Vaccines protect hundreds of millions of people every year from a host of diseases that have the potential to take millions of lives. When administered to enough of the population they can even eradicate the disease altogether. For example,...

Innovation and cutting-edge technology to reduce Research and Development time and costs: InSilicoTrials, a company with broad expertise in Computational Modeling and Simulation, IT and cloud solutions for the healthcare sector, and Galileo Research established a partnership to apply...

Velocity Clinical Research announces it has acquired two multi-site companies, VitaLink Research and the National Research Institute, for an undisclosed amount. The double acquisition adds 11 sites to Velocity’s existing 18, making it the largest fully integrated site management...

Anaqua, the leading innovation and intellectual property management technology provider, announced that global medical products and technologies group ConvaTec will use Anaqua’s AQX platform to help more effectively manage their valuable patent and trademark portfolios. The agreement further strengthens Anaqua’s...

Pfizer Inc. and BioNTech SE announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21...

Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i , for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO),...

Valneva SE, a specialty vaccine company, announced that it has completed recruitment of the initial cohort of elderly participants in Valneva’s Phase 3 trial, VLA2001-304, of its inactivated COVID-19 vaccine candidate, VLA2001. 300 volunteers aged 56 years and older have...